Menu Search
Equities

GSK plc

GSK:LSE

GSK plc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,604.00
  • Today's Change-5.50 / -0.34%
  • Shares traded19.85m
  • 1 Year change+6.55%
  • Beta0.5726
Data delayed at least 20 minutes, as of Sep 18 2024 16:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy5
Outperform6
Hold10
Sell3
Strong Sell0

Share price forecast in GBX

The 22 analysts offering 12 month price targets for GSK plc have a median target of 1,810.00, with a high estimate of 2,640.00 and a low estimate of 1,420.00. The median estimate represents a 12.46% increase from the last price of 1,609.50.
High64.0%2,640.00
Med12.5%1,810.00
Low-11.8%1,420.00

Dividends in GBX

In 2023, GSK plc reported a dividend of 0.58 GBP, which represents a 5.31% decrease from last year. The 19 analysts covering the company expect dividends of 0.60 GBP for the upcoming fiscal year, an increase of 3.79%.
Div growth (TTM)-5.31%
More ▼

Earnings history & estimates in GBX

On Jul 31, 2024, GSK plc reported 2nd quarter 2024 earnings of 43.40 per share. This result exceeded the 37.87 consensus of the 8 analysts covering the company and exceeded last year's 2nd quarter results by 11.86%.
The next earnings announcement is expected on Oct 30, 2024.
Average growth rate+9.27%
GSK plc reported annual 2023 earnings of 155.10 per share on Jan 31, 2024.
Average growth rate+0.24%
More ▼

Revenue history & estimates in GBP

GlaxoSmithKline plc had 2nd quarter 2024 revenues of 7.88bn. This bettered the 7.47bn consensus of the 9 analysts covering the company. This was 13.42% above the prior year's 2nd quarter results.
Average growth rate+2.71%
GlaxoSmithKline plc had revenues for the full year 2023 of 30.33bn. This was 3.42% above the prior year's results.
Average growth rate-1.10%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.